BS
Therapeutic Areas
Tonix Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| TNX-102 SL | Acute Stress Disorder (ASD) | Phase 2 |
| TNX-1500 | Organ Transplant Rejection / Autoimmune Disorders | Phase 1 |
| TNX-2900 | Prader-Willi Syndrome (PWS) | Phase 2 Ready |
| TNX-1900 | Migraine and Craniofacial Pain | Phase 1 |
| TNX-4800 | Prevention of Lyme Disease | Phase 1 |
| TNX-801 | Prevention of Mpox or Smallpox | Preclinical |
| TNX-1700 | Gastric and Colorectal Cancer | Preclinical |
| TNX-4200 | Not Specified (Target: CD45) | Preclinical |
Leadership Team at Tonix Pharmaceuticals
SL
Seth Lederman
Co-Founder, CEO & Chairman
GS
Gregory Sullivan
Chief Medical Officer
JE
Jessica Edgar Morris
Chief Operating Officer
SF
Siobhan Fogarty
Chief Technical Officer
SB
Sina Bavari
EVP, Infectious Disease R&D
BD
Bruce Daugherty
EVP, Research
TE
Thomas Englese
EVP, Commercial Operations
DR
Darryl Rideout
EVP, Experimental Chemistry
ZR
Zeil Rosenberg
EVP, Medical
II
Irina Ishak
General Counsel